azenosertib

Phase 2

00%

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

Q4 '26

ZNTLPhase 2$263M

azenosertib Phase 2 Est. Readout

azenosertib• High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer170

Q4 2026~QConfirmedSTALE

00%

Competitive Landscape

1 competitor in High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Drug Information

Target Indication

High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Clinical Trial

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

ZNTL

Zentalis Pharmaceuticals, Inc.

Related Pipeline

Amyloidosis

Ovarian Cancer

Uterine Serous Carcinoma

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts